PERSPECTA

News from every angle

← Back to headlines

Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand

26 Feb, 02:18 — 26 Feb, 02:18
PostShare
ℹOnly 1 source covers this story

Read at source (1 outlet)

seeking-alpha1h ago

Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand

Read full article →

Related Stories

Davao Region Workers to Receive P20-P30 Daily Wage Hike

just now

Paramount Boosts Offer for Warner Bros. Discovery, Rivaling Netflix

18m ago

Joby Aviation Sets 2026 Revenue Target and Operational Plans

18m ago

IMF urges US to work with partners to ease trade restrictions

20m ago